Veeravenkata Garikiparthy

Veeravenkata Garikiparthy

Auto-generated profile, based on publicly available information

Veeravenkata Garikiparthy

Department of Internal Medicine Texas Tech University Health Science Center El Paso El Paso Texas USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Digital Health
Verified
Journal Article
Open access
SJSarah Johnson
Sarah Johnson
JAJesse Allen
Jesse Allen
LFLorena Fernandez
Lorena Fernandez
VGVeeravenkata Garikiparthy
Veeravenkata Garikiparthy
LRLaura Renovato
Laura Renovato
JCJessica A Chacon
Jessica A Chacon
El Paso, Texas, like many communities along the United States/Mexico border, suffers from a lack of access to many social determinants of health, especially in low-income neighborhoods. These long-standing problems have only been exacerbated by the COVID-19 pandemic. The Texas Tech University Health Sciences Center El Paso Health Education and Awareness Team (EP-HEAT) is an organization that was established with a focus on disseminating health information to the community. EP-HEAT received funding from Microsoft Corporation to facilitate technology education workshops for underserved populations. These workshops were held in English and Spanish and attempted to improve social determinants of health in the community which can be negatively exacerbated by a lack of digital inclusion. Community members who attended workshops completed a LinkedIn Learning Path, or both were offered an anonymous post-course survey with a mixed method questionnaire on how their knowledge of basic technology or job skills was improved by engaging with the provided workshops and learning paths. Overall, 80% of community members who participated in the workshops reported learning a new skill, and 91% of participants who started a LinkedIn Learning Path were able to finish. The workshops were well received by the community and highlighted the potential for these programs to enhance digital skills and upward workforce mobility.

8 April 2026 in European Journal of Haematology
Verified
Journal Article
Open access
MPManas Pustake
Manas Pustake
SDShubhangi Deoker
Shubhangi Deoker
VGVeeravenkata Garikiparthy
Veeravenkata Garikiparthy
KSKunal Sharma
Kunal Sharma
LKLakshmi Kattamuri
Lakshmi Kattamuri
ADAbhinav Deol
Abhinav Deol
Background: Platelet transfusion is commonly used to reduce bleeding risk in platelet consumptive disorders. However, platelets may also promote thromboinflammatory pathways, and contemporary data evaluating the association between platelet transfusion, thrombosis, and mortality in this population are limited. Methods: We performed a retrospective cohort study using the National Inpatient Sample from 2018 to 2021. Non‐elective hospitalizations with immune thrombocytopenic purpura, thrombotic thrombocytopenic purpura, heparin‐induced thrombocytopenia, or other primary thrombocytopenias were included. The exposure was receipt of any platelet transfusion during hospitalization. Primary outcomes were in‐hospital mortality and in‐hospital thrombotic events, defined as venous thromboembolism or arterial thrombosis using ICD‐10‐CM codes. Inverse probability of treatment weighting and survey‐weighted logistic regression were used to adjust for demographics, comorbidities, illness severity, major bleeding, and disease‐specific therapies. Results: Among 67 405 hospitalizations (337 705 weighted national estimates), 10.5% received platelet transfusion. Mortality was higher in transfused versus nontransfused hospitalizations (9.5% vs. 6.1%; p < 0.001). After adjustment, platelet transfusion was associated with increased odds of in‐hospital mortality (adjusted odds ratio [aOR], 1.42; 95% CI: 1.28–1.60) and thrombosis (any thrombosis: aOR, 1.28; 95% CI: 1.18–1.39). Associations were observed for venous (aOR, 1.39) and arterial thrombosis (aOR, 1.15). Thrombotic risk persisted among hospitalizations without major bleeding but was attenuated with major bleeding. Intravenous immunoglobulin was associated with higher odds of thrombosis, while plasma exchange was associated with lower odds. Conclusion: In patients hospitalized with platelet consumptive disorders, platelet transfusion was associated with higher odds of in‐hospital thrombosis and mortality, supporting judicious, indication‐driven transfusion practices.